Welcome to our dedicated page for ZIOP news (Ticker: ZIOP), a resource for investors and traders seeking the latest updates and insights on ZIOP stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ZIOP's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ZIOP's position in the market.
Ziopharm Oncology (Nasdaq: ZIOP) reported a net loss of $20.3 million for Q3 2020, improving from a net loss of $74 million in Q3 2019. The Company plans to file an IND for its TCR-T trial in Q1 2021 and has made significant progress in its cancer therapies. Key milestones include acceptance of three abstracts at the Society for Neuro-Oncology and receiving Rare Pediatric Disease Designation for its Controlled IL-12 program. Operating expenses rose due to increased manufacturing and legal costs, with cash and equivalents totaling $135.5 million as of September 30, 2020.
WaterMill Asset Management, owning 3.3% of Ziopharm Oncology (ZIOP), is urging shareholders to support its proposals to reconstitute the Board of Directors. The activist campaign aims to remove four incumbent directors and elect three independent nominees to drive shareholder value, citing significant underperformance since 2015. WaterMill's analysis highlights Ziopharm's negative total shareholder returns of -39.31% over one year and calls for urgent boardroom changes to protect shareholder interests and improve governance. Shareholders are encouraged to vote using the WHITE consent card by December 11, 2020.
On November 2, 2020, Ziopharm Oncology, Inc. (ZIOP) announced its definitive consent revocation against WaterMill Asset Management's solicitation to remove four Board members. Ziopharm emphasizes its commitment to shareholder value through strategic Board refreshment and highlights recent successes in therapy development, securing $200 million funding, and maintaining a cash position of $153 million. The company urges shareholders to support its current Board by signing the GREEN Consent Revocation Card, rejecting WaterMill's proposals, which it views as self-serving and detrimental to its strategic goals.
WaterMill Asset Management, owning approximately 3.3% of Ziopharm Oncology (ZIOP), aims to reconstitute the Board of Directors. They propose removing four incumbent directors and electing three independent candidates to improve corporate governance and shareholder value. WaterMill highlights a decline of over 75% in Ziopharm's share price over five years and nearly 40% in the last year. The campaign seeks to address shareholder dissatisfaction and enhance strategic planning. The consent deadline for shareholders to act is December 11, 2020.
Ziopharm Oncology, Inc. (Nasdaq: ZIOP) will host a conference call and webcast on November 5, 2020, at 4:30 pm EDT to discuss the third-quarter financial results for the period ending September 30, 2020. The call can be accessed by phone or through the Company’s website, where a recording will be available for two weeks post-event. Ziopharm focuses on immuno-oncology, using its Sleeping Beauty platform for effective T-cell therapies and gene therapy, enhancing treatment options for solid and blood cancers.
BOSTON, Oct. 16, 2020 — Ziopharm Oncology (Nasdaq: ZIOP) announced it received a consent solicitation notice from WaterMill Asset Management, which owns 7,173,650 shares of Ziopharm. The solicitation aims to remove four board members and elect three new ones, including Robert W. Postma. Ziopharm's management emphasizes their commitment to shareholder engagement and maintaining a refreshed board, stating that seven of the eight directors are independent. The company advises shareholders to refrain from action while they review the notice.
On September 22, 2020, Ziopharm Oncology (ZIOP) appointed J. Kevin Buchi to its Board of Directors as Chair of the Audit Committee, succeeding Doug Pagán, who has stepped down. Buchi has extensive life sciences experience, previously serving as CEO of Cephalon during its $6.8 billion merger with Teva Pharmaceuticals. The company is aiming to transition into a commercial-stage entity with a robust pipeline of clinical programs targeting solid tumors. The Board is evolving to meet the business's needs as it continues its innovative efforts in immuno-oncology.
Ziopharm Oncology (ZIOP) appointed four new members to its Scientific Advisory Board (SAB) to enhance its immunotherapy pipeline aimed at treating solid tumors. The board will be chaired by Carl June, M.D., who emphasized the exceptional expertise of the new advisors: Adi Barzel, Gavin Dunn, Matthew Porteus, and Kole Roybal. Each brings significant experience in immunology and gene therapy, potentially accelerating the company’s development of innovative treatments. The announcement signals Ziopharm's commitment to advancing its therapeutic approach in the competitive oncology market.
BOSTON, Sept. 10, 2020 – Ziopharm Oncology (Nasdaq: ZIOP) announced that its CEO, Laurence Cooper, will participate in two conferences: the H.C. Wainwright 22nd Annual Global Investment Conference on Sept. 16 at 9:00 a.m. ET, and the Cantor Virtual Global Healthcare Conference on Sept. 17 at 1:20 p.m. ET. Live webcasts and recordings will be available in the Investors section of the company’s website. Ziopharm focuses on developing innovative therapies for solid tumors using a non-viral gene transfer platform and collaborates with leading cancer research institutions.
Ziopharm Oncology (ZIOP) announced a significant update with the completion of enrollment in its phase 2 trial of Controlled IL-12 combined with Libtayo, targeting recurrent glioblastoma. The company also initiated a phase 1/2 pediatric trial for DIPG and is advancing TCR-T trials in collaboration with NCI and MD Anderson. Financially, the company reported a net loss of $18.6 million for Q2 2020, the same EPS of $(0.09) as in Q2 2019, alongside increased R&D and administrative expenses. The cash position stands at $153.5 million, ensuring operational stability.
